Paradiem LLC Sells 8,689 Shares of Abbott Laboratories $ABT

Paradiem LLC lowered its holdings in Abbott Laboratories (NYSE:ABT) by 15.9% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 45,940 shares of the healthcare product maker’s stock after selling 8,689 shares during the quarter. Paradiem LLC’s holdings in Abbott Laboratories were worth $4,717,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of ABT. J. Stern & Co. LLP grew its stake in shares of Abbott Laboratories by 12,439.6% in the fourth quarter. J. Stern & Co. LLP now owns 39,319,009 shares of the healthcare product maker’s stock worth $4,926,279,000 after acquiring an additional 39,005,451 shares during the last quarter. Norges Bank bought a new stake in Abbott Laboratories in the 4th quarter valued at $2,938,892,000. Assenagon Asset Management S.A. boosted its holdings in Abbott Laboratories by 303.0% in the 1st quarter. Assenagon Asset Management S.A. now owns 4,429,571 shares of the healthcare product maker’s stock valued at $454,784,000 after purchasing an additional 3,330,368 shares during the period. Ninety One UK Ltd acquired a new stake in Abbott Laboratories in the 4th quarter worth $336,815,000. Finally, Vanguard Group Inc. increased its holdings in shares of Abbott Laboratories by 1.4% during the 4th quarter. Vanguard Group Inc. now owns 175,556,716 shares of the healthcare product maker’s stock worth $21,995,501,000 after purchasing an additional 2,402,408 shares during the period. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on ABT shares. Wells Fargo & Company reduced their target price on shares of Abbott Laboratories from $122.00 to $109.00 and set an “overweight” rating for the company in a research note on Friday, April 17th. Citigroup cut their price target on Abbott Laboratories from $136.00 to $108.00 and set a “buy” rating for the company in a report on Friday, April 17th. Daiwa Securities Group downgraded Abbott Laboratories from an “outperform” rating to a “neutral” rating and set a $92.00 price objective for the company. in a research report on Wednesday, April 22nd. Piper Sandler restated an “overweight” rating and set a $115.00 price objective on shares of Abbott Laboratories in a research report on Monday, June 22nd. Finally, JPMorgan Chase & Co. reduced their target price on Abbott Laboratories from $123.00 to $110.00 and set an “overweight” rating for the company in a research report on Friday, April 17th. Three analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Abbott Laboratories has an average rating of “Moderate Buy” and a consensus target price of $118.42.

Abbott Laboratories Stock Up 0.0%

Shares of ABT opened at $93.97 on Monday. The company has a quick ratio of 1.01, a current ratio of 1.39 and a debt-to-equity ratio of 0.56. The company has a 50-day moving average price of $89.21 and a two-hundred day moving average price of $103.09. The stock has a market cap of $163.69 billion, a price-to-earnings ratio of 26.32, a P/E/G ratio of 1.62 and a beta of 0.61. Abbott Laboratories has a 12 month low of $81.97 and a 12 month high of $137.49.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings data on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share for the quarter, beating the consensus estimate of $1.14 by $0.01. The company had revenue of $11.16 billion for the quarter, compared to analyst estimates of $10.99 billion. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.The company’s revenue was up 7.8% compared to the same quarter last year. During the same period in the prior year, the company posted $1.09 EPS. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. Equities analysts predict that Abbott Laboratories will post 5.48 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th will be paid a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 2.7%. The ex-dividend date is Wednesday, July 15th. Abbott Laboratories’s dividend payout ratio is currently 70.59%.

Insiders Place Their Bets

In other news, CFO Philip P. Boudreau bought 2,200 shares of the company’s stock in a transaction that occurred on Thursday, April 23rd. The stock was acquired at an average price of $91.50 per share, for a total transaction of $201,300.00. Following the transaction, the chief financial officer directly owned 2,200 shares of the company’s stock, valued at $201,300. This trade represents a ∞ increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Daniel J. Starks purchased 10,000 shares of the business’s stock in a transaction that occurred on Monday, April 27th. The shares were purchased at an average cost of $92.65 per share, with a total value of $926,500.00. Following the completion of the acquisition, the director directly owned 6,751,103 shares in the company, valued at $625,489,692.95. The trade was a 0.15% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. 0.46% of the stock is currently owned by company insiders.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.